MAP Pharmaceuticals (NASDAQ:MAPP)
| CAPS Rating |
|
|---|---|
| Open | $15.34 |
| Previous Close | $15.49 |
| Daily Range | $15.02 - $15.43 |
| 52-Week Range | $10.54 - $17.35 |
| Market Cap | $464.15M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 65,534 |
| Average Daily Volume | 0 |
MAPP
VS S&P 500 (SPY)
How do you think MAPP will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MAPP Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MAPP News and Commentary
- Investing Ideas: The Biggest 8-K Filings Over the Last 24 Hours – NASDAQ
- Top 10 Undervalued Stocks With Large Cash Cushions – The Motley Fool
- Monday's High-Volume Gainers With Conservative Accounting Practices – SeekingAlpha
- 2nd UPDATE: Allergan 1Q Earnings Sink On Charges; Outlook Raised – SmartMoney
- UPDATE: Allergan 1Q Earnings Sink On Charges; Outlook Raised – SmartMoney
- George Soros' (Extremely Successful) Long Term Holdings – SeekingAlpha
- George Soros's (Extremely Successful) Long-Term Holdings – SeekingAlpha
- Contrarian Ideas: 6 Beaten Up Stocks With Rising Put Volume – SeekingAlpha
- Top 24 Small Cap Stocks Being Chased by Smart Money – SeekingAlpha
- UPDATE: Allergan 4Q Profit Up 19%; EPS Outlooks Below Street – SmartMoney
- Allergan CEO: Would Consider Expanded Agreement On Levadex – SmartMoney
- Allergan 4Q Profit Up 19%; EPS Outlooks Miss Street Forecasts – SmartMoney
- CORRECT:UPDATE: Allergan To Help Sell Map Pharma's Migraine Treatment – SmartMoney
- UPDATE: Allergan To Help Sell Map Pharma's Migraine Treatment – SmartMoney
- Allergan To Pay Map Pharma $60 Million To Co-Promote Levadex – SmartMoney
- Momentum Ideas: 15 Undervalued Stocks Approaching An Inflection Point – NASDAQ
- Wednesday's High Volume Gainers With Bullish Options Sentiment – SeekingAlpha
- Map Pharmaceuticals Sees Positive Study Results For Migraine Drug Levadex – SmartMoney
- UPDATE 1-MAP says FDA waives second trial for migraine drug – Reuters
- 3 Stocks Ready to Roar – The Motley Fool
RSS Headlines
Fool UK
